Navigation Links
Sanarus Announces Partnership With Leading US Breast Care Physicians for the Next Generation Visica 2(TM) Treatment System for Fibroadenomas
Date:9/28/2007

NEW ORLEANS, Sept. 28 /PRNewswire/ -- Sanarus Medical today announced a partnership with leading breast care physicians from select centers across the country. These Centers, including breast care physicians from Connecticut to California, will work in partnership with Sanarus to increase the awareness and availability of an innovative, non-surgical treatment option for women with benign breast tumors, known as fibroadenomas. Sanarus will host a gathering of these new Centers prior to the American College of Surgeons (ACS) annual meeting in New Orleans.

In partnership with Sanarus, these centers will participate in regional and national efforts to increase patient and primary care physician awareness of the Visica 2 treatment as a minimally invasive, highly safe and effective treatment alternative to surgical excision. These Centers will participate in a patient registry to document the clinical outcomes and patient satisfaction rates following Visica 2 treatment.

Additionally, these Centers are dedicated to expanding private health insurance coverage of this important treatment option, making it more widely available to women across the country. Sanarus plans to include as many as 20 centers in this program before the end of 2007.

"I am very pleased to be a part of this important program that will offer more options to my patients. This technology makes cryoablation easier and faster than ever before and not only does that make sense for my practice, it makes the procedure very appealing to my patients," said Andrew Kenler, M.D., a surgeon from Connecticut and one of the newly created Visica 2 Reference Centers.

Visica 2 Treatment System

The original Visica(R) Treatment System received FDA market clearance in 2002 and has been proven highly safe and effective with more than 1,500 fibroadenomas treated. The innovative Visica 2 System has been available at select sites since April of 2007. The Visica 2 Treatment System uses liquid nitrogen as the freezing agent, obviating the need for large, high pressure tanks of argon and helium used in the original Visica Treatment System. Because nitrogen operates at colder temperatures than argon, it allows for a more efficient, faster treatment. The procedure can be completed in the physician's office, with most treatment times under 15 minutes. Early experience has shown excellent physician and patient satisfaction with the new Visica 2 Treatment System.

Sanarus will be demonstrating this ground breaking system at the American College of Surgeons (ACS) meeting, October 7-11 in New Orleans.

Sanarus Medical is based in Pleasanton, CA and is focused on providing patients and physicians with minimally invasive, office-based breast care management solutions from diagnosis and treatment to follow up. Using cryoablation technology, Sanarus has developed proprietary technologies to provide breast surgeons and radiologists with a comprehensive and minimally invasive way to diagnose and treat breast patients. The Sanarus technologies change the way that patients are managed, from an operating room-based, surgically intensive care pathway to a more comfortable, cost effective, office-based care pathway. Sanarus is dedicated to women's breast health and to providing minimally invasive solutions for the diagnosis and treatment of breast disease solutions that can help eliminate pain and improve quality of life. The company's website is http://www.sanarus.com.


'/>"/>
SOURCE Sanarus Medical, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. PM announces a new health care order for India
2. Ramdoss Announces Introduction of RCH-II
3. Britain Announces Third Transfusion Related Mad Cow Case
4. Gates Foundation Announces $287 Million In Grants Towards AIDS Vaccine
5. Tibet Announces the Dalai Lama’s Tour of South Americ
6. NHS announces further Cost cutting Measures
7. Indian PM Announces Of Setting Up India Study Center At Tashkent
8. PowderMed Announces Needle-Less Flu Vaccine
9. Malaysia Announces Prison term On People Donating HIV-Contaminated Blood
10. Australian Government Announces Survey To Tackle Childhood Obesity
11. New Zealand Announces 10-year Plan For Betterment Of Mental Health Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... 07, 2016 , ... Students attending Envision’s summer 2017 ... get hands-on experience in an emergency medical simulation, When Care is Hours Away. ... real-life medical skills that are critical success in a future career and beyond. ...
(Date:12/7/2016)... CITY, UTAH (PRWEB) , ... December 07, 2016 ... ... today announced the release of Smart Device Remote Control through a new partnership ... across all platforms and strengthens its mobile solutions to help businesses maximize their ...
(Date:12/7/2016)... ... December 07, 2016 , ... Castle Dermatology Institute is now ... to restore a more youthful appearance to the face. Dr. Peyman Ghasri and Dr. ... a variety of other treatments, to rejuvenate and renew the facial appearance. , ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... now promoting to the US market its advanced highly customizable contact technology solutions. ... ODU TURNTAC®. These advanced technologies are ideal for a wide range of applications ...
(Date:12/7/2016)... ... December 07, 2016 , ... AlignLife clinics nationwide are ... children are not fortunate enough to receive bountiful gifts wrapped tightly under a Christmas ... bring to the children of the world. , In exchange for generous donations, customers ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... -- REPORT OBJECTIVES The report "SPF ... on a market segment, based on geography. Market ... the report. The primary objectives of this report ... through detailed segmentation, 2) market size and forecasts, ... market situation, trends, 3) detailed analysis of current ...
(Date:12/7/2016)... YORK , Dec. 7, 2016 ... report on pulmonary drugs studies the current as ... The stakeholders of this report include companies and ... various pulmonary/respiratory drugs and/or drug-device combinations as well ... This report comprises an elaborate executive summary along ...
(Date:12/7/2016)... DIEGO , Dec. 7, 2016   Arena ... announced that it has completed enrollment in the ralinepag ... receptor agonist targeting the prostacyclin pathway for the treatment ... 60 patients at sites globally. "This marks ... is evidence of our strategic focus on our pipeline," ...
Breaking Medicine Technology: